Cargando…

Using four‐dimensional computed tomography images to optimize the internal target volume when using volume‐modulated arc therapy to treat moving targets

In this work we used 4D dose calculations, which include the effects of shape deformations, to investigate an alternative approach to creating the ITV. We hypothesized that instead of needing images from all the breathing phases in the 4D CT dataset to create the outer envelope used for treatment pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yakoumakis, Nikolaos, Winey, Brian, Killoran, Joseph, Mayo, Charles, Niedermayr, Thomas, Panayiotakis, George, Lingos, Tania, Court, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718550/
https://www.ncbi.nlm.nih.gov/pubmed/23149778
http://dx.doi.org/10.1120/jacmp.v13i6.3850
Descripción
Sumario:In this work we used 4D dose calculations, which include the effects of shape deformations, to investigate an alternative approach to creating the ITV. We hypothesized that instead of needing images from all the breathing phases in the 4D CT dataset to create the outer envelope used for treatment planning, it is possible to exclude images from the phases closest to the inhale phase. We used 4D CT images from 10 patients with lung cancer. For each patient, we drew a gross tumor volume on the exhale‐phase image and propagated this to the images from other phases in the 4D CT dataset using commercial image registration software. We created four different ITVs using the N phases closest to the exhale phase (where [Formula: see text] , 8, 7, 6). For each ITV contour, we created a volume‐modulated arc therapy plan on the exhale‐phase CT and normalized it so that the prescribed dose covered at least 95% of the ITV. Each plan was applied to CT images from each CT phase (phases 1–10), and the calculated doses were then mapped to the exhale phase using deformable registration. The effect of the motion was quantified using the dose to 95% of the target on the exhale phase [Formula: see text] and tumor control probability. For the three‐dimensional and 4D dose calculations of the plan where [Formula: see text] , differences in the [Formula: see text] value varied from 3% to 14%, with an average difference of 7%. For 9 of the 10 patients, the reduction in [Formula: see text] was less than 5% if eight phases were used to create the ITV. For three of the 10 patients, the reduction in the [Formula: see text] was less than 5% if seven phases were used to create the ITV. We were unsuccessful in creating a general rule that could be used to create the ITV. Some reduction (8/10 phases) was possible for most, but not all, of the patients, and the ITV reduction was small. PACS number: 87.55.D‐